Neurogenomics Market to Reach $4.68 Billion by 2031
Meticulous Research®—a leading global market research company, published a research report titled ‘Neurogenomics Market—Global Opportunity Analysis & Industry Forecast to 2031’. According to this latest publication, the neurogenomics market is expected to reach $4.68 Billion by 2031, at a CAGR of 16.6% from 2024 to 2031.
The growth of the neurogenomics market
is driven by the declining costs of sequencing, the increasing prevalence of
neurological disorders, the growing utilization of advanced sequencing
technologies in disease diagnostics & precision medicine, increasing
pharmaceutical R&D expenditures, improvements in regulatory &
reimbursement scenarios for gene sequencing, rising healthcare expenditures,
increasing funding for research activities, the growing need for the early
detection & prevention of neurological disorders, technological
advancements in neurogenomics products, and government initiatives promoting
the use of sequencing in clinical & research applications. However, the
high prices of neurogenomics products, the low chances of identifying positive actionable
mutations for precision medicine, and ethical & legal issues related to
sequencing-based diagnosis are factors restraining the growth of this market.
Furthermore, the increasing adoption
of targeted therapies, emerging economies, and rising awareness regarding
neurological disorders are expected to generate growth opportunities for market
stakeholders. However, the dynamic regulatory landscape, the limited expertise
& sequencing capabilities of small & medium-sized laboratories, the
shortage of sequencing professionals, and the high capital investments required
for sequencing setups are major challenges impacting the growth of the
neurogenomics market.
Key Players
The neurogenomics market is moderately
competitive due to the presence of many large and small-sized regional and
local players. The key players operating in the neurogenomics market are
Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La
Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc.
(U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.),
Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI
Tech Co., Ltd. (China). The neurogenomics market is segmented based on
offering, application, end user, and geography.
Among the offerings studied in this
report, the next-generation
sequencing (NGS) segment is anticipated to hold the dominant position, with a
share of 63.9% of the market in 2024. The significant
prevalence of neurological disorders, increasing healthcare costs, and
extensive initiatives aimed at enhancing diagnostic and treatment methods
through next-generation sequencing (NGS) are key factors driving the segment's
dominance in the neurogenomics market.
Among the applications studied in
this report, the research
applications segment is anticipated to hold the dominant position, with a share
of 61.6% of the market in 2024. The swift integration of
advanced solutions such as next-generation sequencing (NGS), PCR, and
microarrays in academic and research institutions, substantial investments in
genomics research, and the increasing demand for personalized medicine are
driving the segment's dominance in the neurogenomics market.
Among the end users studied in this
report, the pharmaceutical
& biotechnology companies segment is anticipated to hold the dominant
position, with a share of 44.6% of the market in 2024.
Elevated R&D expenditures by pharmaceutical and biotechnology companies,
which facilitate the adoption of advanced solutions such as next-generation
sequencing, microarrays, and PCR technologies, along with the high incidence of
neurological disorders, are key factors contributing to the dominance in the
neurogenomics market.
Among the geographies studied in
this report, North America is
anticipated to hold the dominant position, with a share of 47.2% of
the market in 2024. The growth of this market can be primarily attributed to
rising R&D expenditures in the pharmaceutical and biotechnology sector, the
presence of major market players in the region, supportive government
initiatives for genomics research, expanding applications of sequencing-based
research, the increasing prevalence of neurological diseases, and a favorable
reimbursement landscape.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=6019
Key Questions Answered in the
Report:
·
What is
the revenue generated from the neurogenomics market globally, based on
offering, application, and end user?
·
At what
rate is the demand for neurogenomics solutions projected to grow globally for
the next five to seven years?
·
What are
the historical market size and growth rate for the neurogenomics market?
·
What are
the major factors impacting the growth of this market?
·
What are
the major opportunities for existing players and new entrants in the market?
·
Which
offering, application, and end-user segments are expected to create major
traction for the players in this market?
·
Who are
the major players in the neurogenomics market? What are their specific product
offerings in this market?
·
What are
the recent developments in the neurogenomics market? What are the impacts of
these strategic developments?
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment